Page 3 - Weight Loss

Think skipping meals is good for your health? Here's what you should know

Skipping meals can increase stress, disrupt hormones, and worsen metabolism. Intermittent fasting offers a smarter, mindful and beneficial approach to eating patterns

Can Mounjaro transform obesity care? ₹50 crore sales in three months

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

Fact-check | Can Lemon Water Burn Fat? Experts Bust 15 Weight Loss Myths | Health with BS

Does lemon water really burn fat? Or is it just another wellness myth? ???? In this fact-check video, top health and nutrition experts bust 15 of the most common weight loss myths

Can lemon water burn fat? Experts bust 15 weight loss myths you believe

From lemon water and detox drinks to skipping rice and sweating more, experts separate fat-loss facts from fiction to help you focus on what works

Anti-obesity mkt heats up as Mounjaro's Kwikpen version gets India approval

With CDSCO approval, Mounjaro to be available in a Kwikpen format; this comes a day after Wegovy's India launch, intensifying competition in weight-loss treatment

India approves Eli Lilly's Mounjaro pen for diabetes, weight control

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 diabetes and chronic weight management

Obesity drug race begins: Wegovy launches in India | Novo Nordisk | Weight loss drug | Pharma sector

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly’s launch of Mounjaro just 3 months ago.

New data shows just how powerful the next weight-loss drugs may be

The drugs in development include a pill that a new trial suggests is about as effective as Ozempic

Novo Nordisk launches Wegovy in India to tackle obesity and heart risk

Wegovy is India's first weekly injectable approved for both long-term weight loss and reducing heart risks in obese and overweight adults

Novo Nordisk launches blockbuster weight-loss drug Wegovy in India

The 1.75 mg and 2.4 mg doses will be priced at ₹24,280, and 2.4 mg will be priced at ₹26,050 for a month

India's response to obesity drug Mounjaro 'positive', says Eli Lilly

Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May

Obesity injections may have less weight loss effect in reality: Study

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower

New mechanism rewires cell energy processing for weight loss, shows study

Led by researchers at NYU Grossman School of Medicine, the study reveals key details about how cells process fuels like carbohydrates and fats, and how cysteine depletion affects tissues

Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies

Why Ozempic maker Novo Nordisk is losing its lead in weight-loss drugs

The Danish drugmaker led the obesity revolution with Ozempic and Wegovy but now lags Eli Lilly in efficacy, trials, and strategy in a $150-bn market

Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

Ozempic teeth, face and tongue: Side effects of GLP-1 drugs explained

As the use of weight-loss injections rises, users report effects like Ozempic face, tongue, and teeth- here is what these mean and how to manage them

What happens to your weight after stopping Ozempic, Wegovy or Mounjaro?

Many people using GLP-1 weight-loss drugs like Ozempic, Wegovy or Mounjaro regain the weight after stopping- experts explain why it happens, who's at risk, and how to keep the weight off

Eli Lilly's tirzepatide shows superior weight loss to Novo's semaglutide

Phase 3b trial finds Lilly's tirzepatide delivers higher average weight loss and waist reduction than Novo's semaglutide in people with obesity or overweight

Mounjaro helps users lose more weight than Wegovy, new trial reveals

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs